Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Apr;10(4):396-401.
doi: 10.1038/nm1023. Epub 2004 Mar 21.

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease

Edith Passage  1 , Jean Chrétien Norreel, Pauline Noack-Fraissignes, Véronique Sanguedolce, Josette Pizant, Xavier Thirion, Andrée Robaglia-Schlupp, Jean François Pellissier, Michel Fontés
Affiliations

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease

Edith Passage et al. Nat Med. 2004 Apr.

Abstract

Charcot-Marie-Tooth disease (CMT) is the most common hereditary peripheral neuropathy, affecting 1 in 2,500 people. The only treatment currently available is rehabilitation or corrective surgery. The most frequent form of the disease, CMT-1A, involves abnormal myelination of the peripheral nerves. Here we used a mouse model of CMT-1A to test the ability of ascorbic acid, a known promoter of myelination, to correct the CMT-1A phenotype. Ascorbic acid treatment resulted in substantial amelioration of the CMT-1A phenotype, and reduced the expression of PMP22 to a level below what is necessary to induce the disease phenotype. As ascorbic acid has already been approved by the FDA for other clinical indications, it offers an immediate therapeutic possibility for patients with the disease.

PubMed Disclaimer

Publication types